Overview

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a an open-label, single dose, parallel group study to evaluate the PK of iptacopan in participants with mild, moderate, or severe hepatic impairment compared to matched healthy control participants
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals